FDA Approves Drug To Treat HIV Infection in Newborns
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns
Read original at benzingaStocks · News reference
Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2636#
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 4:04 PM
- Checked
- Jul 31, 2026, 4:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?
Two unvaccinated Pennsylvania residents died of measles, the state’s first deaths in 35 years, as traders see 89% odds of 4,000 U.S. cases.
Read original at benzingaDr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy
Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “quite lethal” amid vaccine policy scrutiny.
Read original at benzingaWall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.
Read original at benzingaGuggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33
Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and raises the price target from $24 to $33.
Read original at benzingaUPDATE: SCYNEXIS Q2 Adj. EPS $(0.57) Misses $(0.51) Estimate, Sales $235.000K Beat $80.330K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.51) by 11.76 percent. This is a 49.11 percent increase over losses of $(1.12) per share from the
Read original at benzinga